ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.
Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.
Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
Location: United States, New Jersey, Princeton
Employees: 1-10
Total raised: $20M
Investors 4
| Date | Name | Website |
| - | Westfield ... | westfieldb... |
| 19.04.2022 | Insight Pa... | insightpar... |
| 07.04.2022 | Innospark ... | innosparkv... |
| 06.09.2025 | CARB-X | carb-x.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.03.2022 | Seed | $20M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.05.2022 | Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron | SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio... |
| 07.03.2022 | ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance | ArrePath, an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, announced that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platf... |
| 04.03.2022 | ArrePath Raises $20M in Seed Financing | Dr. Lloyd Payne, ArrePath President and CEO (Photo: Business Wire) ArrePath, a Princeton, NJ-based anti-infective drug discovery company addressing the global health challenge of drug resistant infections, raised $20m in seed financing. The... |
| 03.03.2022 | Drug discovery startup ArrePath scores $20M and more digital health fundings | Photo: filadendron/Getty Images |
| - | Princeton spinout ArrePath gets $20M to combine AI, imaging in antibiotics R&D | Antibiotic resistance is a growing problem, and it’s one that large pharmaceutical companies have largely abandoned. Some startups are filling the gap, and a new one, ArrePath, has novel molecules with a different approach that could overco... |